Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Clinical and bacteriologic efficacy of telithromycin in patients with bacteremic community-acquired pneumonia
Respiratory Medicine, Volume 100, No. 4, Year 2006
Notification
URL copied to clipboard!
Description
This retrospective analysis was performed to determine the clinical and bacteriologic efficacy of the ketolide antibacterial telithromycin in patients with community-acquired pneumonia (CAP) with pneumococcal bacteremia. Patients ≥13 years old with radiologically confirmed CAP and a positive blood culture for Streptococcus pneumoniae at screening were analyzed from eight multicenter Phase III/IV clinical trials. In four open-label, non-comparative studies, patients received telithromycin 800 mg once daily for 7-10 days. In four randomized, controlled, double-blind, comparative studies, patients received telithromycin 800 mg once daily for 5-10 days or a comparator antimicrobial (amoxicillin 1000 mg three times daily, clarithromycin 500 mg twice daily, or trovafloxacin 200 mg once daily) for 7-10 days. In total, 118 patients (telithromycin, 94/1061 [8.9%]; comparator, 24/244 [9.8%]) had documented pneumococcal bacteremia. Those who were treated with telithromycin achieved a clinical cure rate of 90.2% (74/82, per-protocol population); S. pneumoniae was eradicated in 77/82 (93.9%) bacteremic patients who received telithromycin and 15/19 (78.9%) comparator-treated patients. Clinical cure was also observed among telithromycin-treated bacteremic patients who were infected with penicillin- or erythromycin-resistant strains of S. pneumoniae (5/7 and 8/10, respectively). In conclusion, telithromycin achieves high clinical and bacteriologic cure rates in CAP patients with pneumococcal bacteremia. © 2005 Published by Elsevier Ltd.
Authors & Co-Authors
Carbón, Claude
Unknown Affiliation
Van Rensburg, D. J.
South Africa
Medpark Centre
Hagberg, Lars
Sweden, Gothenburg
Sahlgrenska Universitetssjukhuset
Fogarty, Charles M.
United States, Spartanburg
Spartanburg Pharmaceutical Research
Tellier, Guy
Canada, Quebec
Zoom Intl. Clinical Research Group
Rangaraju, Manickam
France, Gentilly
Sanofi S.a.
Nusrat, Roomi
France, Gentilly
Sanofi S.a.
Statistics
Citations: 7
Authors: 7
Affiliations: 5
Identifiers
Doi:
10.1016/j.rmed.2005.11.007
ISSN:
09546111
Research Areas
Disability
Study Design
Cross Sectional Study
Cohort Study